Skip to content

Evaluation of Effectiveness of Misoprostol in Office Hysteroscopy : A Prospective Randomized Double Blind Placebo Controlled Trial

Evaluation of Effectiveness of Misoprostol in Office Hysteroscopy : A Prospective Randomized Double Blind Placebo Controlled Trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2019/04/018458
Enrollment
100
Registered
2019-04-08
Start date
Unknown
Completion date
Unknown
Last updated
2023-01-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N858- Other specified noninflammatory disorders of uterus

Interventions

Intervention1: MISOPROSTOL: Misoprostol is a Prostaglandin analogue frequently used in Obstetrics and Gynaecology for cervical ripening. Available as 200 microgram tablet. Tab Misoprostol 200 microgra

Sponsors

All India Institute of Medical Sciences New Delhi
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Any premenopausal nulliparous woman undergoing Office Hysteroscopy for any indication as deemed necessary upon clinical evaluation.

Exclusion criteria

Exclusion criteria: 1. Any contraindication for hysteroscopy i. An ongoing viable pregnancy ii. Genital tract malignancy iii. Active per vaginal bleeding iv. Active genital tract infection 2. Any contraindication for Misoprostol i. Hypersensitivity to Misoprostol ii. Uncontrolled severe asthma iii. Chronic liver or kidney disease iv. Porphyrias v. An ongoing viable pregnancy 3. Any contraindication for Clotrimazole i. Hypersensitivity to Clotrimazole

Design outcomes

Primary

MeasureTime frame
Ease of doing Office Hysteroscopy in premenopausal nulliparous women after vaginal application of 200 microgram of Misoprostol 4 hours prior to the procedure in comparison with placebo.Timepoint: 1)Time taken for cervical passage: starting when the scope touches the external os (Time point T1) and ending when leaving the cervix at the point of passing the internal os and entering uterine cavity (Time point T2). 2) Total operating time:- time taken in minutes starting when the hysteroscope touches the labia at the beginning of procedure (Time point T0) and ending when the scope leaves the vaginal canal after completion of procedure (Time point T3).

Secondary

MeasureTime frame
Pain relief by vaginal application of 200 microgram Misoprostol in premenopausal nulliparous women 4 hours prior to Office Hysteroscopy in comparison with placeboTimepoint: Pain score as perceived by the patient during the procedure (Time point T0 to T3) and at 30 minutes after the procedure ( Time point T4) on a Visual Analogue Scale (VAS) ranging from 0 to 10 where â??0â?? represents â??no painâ?? and â??10â?? represents â??unbearable painâ??.

Countries

India

Contacts

Public ContactDr Vinod G nair

ALL INDIA INSTITUTE OF MEDICAL SCIENCES

drkkroy2003@gmail.com9811317011

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026